Higher expression level of CISD1 was found to be associated with worse clinical outcome (P = 4E-04, log-rank test) (Figure 4E), and high expression of ATP7B was significantly associated with long survival time of breast cancer patients (P = 0.0203, log-rank test) (Figure 4F). Here, ATP7B is linked to breast carcinoma.